PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Stock Information for Femasys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Femasys Inc.

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Announces Final Results of Tender Offer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.